Vineet Laboratories Limited
All news and filings related to Vineet Laboratories Limited.
View all news & filings- Medium impact
Vineet Laboratories Limited: Statutory Auditors M/s. NSVR & Associates LLP Resign
M/s. NSVR & Associates LLP, Statutory Auditor of Vineet Laboratories Limited, has resigned. The resignation is effective September 29, 2026, due to other commitments. The Audit Committee and Board will appoint new auditors. The company has fulfilled SEBI disclosure requirements.
Read the summary - Low impact
Vineet Laboratories: Trading Window Closed for Q2FY27 Results
Vineet Laboratories Limited will close its trading window from October 1, 2026, until 48 hours post-announcement of Q2FY27 results. This is in compliance with SEBI regulations. The company will announce the board meeting date for financial results declaration soon.
Read the summary - Low impact
Vineet Laboratories gets 2-month extension for 10th AGM till Nov 30, 2026
Vineet Laboratories Limited has been granted a two-month extension by the Registrar of Companies for its 10th Annual General Meeting (AGM). The AGM for the financial year ended March 31, 2026, must now be held by November 30, 2026. The ROC approval was received on September 18, 2026.
Read the summary - Low impact
Vineet Labs Clarifies Financial Results Date Error, Board Approved Results on Aug 25, 2026
Vineet Laboratories Limited corrected a typo in its Q4 FY26 results, confirming board approval on August 25, 2026, not May 30, 2026. The company approved audited standalone financial results and statements for the year ended March 31, 2026, with an unmodified audit opinion. Total assets were ₹12,478.34 lakh, and it reported a profit before tax of ₹128.27 lakh for FY26.
Read the summary - Medium impact
Vineet Laboratories Approves Audited FY26 Standalone Results, Reports Net Profit of ₹72.51 Lakh
Vineet Laboratories Limited's Board approved audited standalone financial results for FY26. The company reported a net profit of ₹72.51 lakh for Q4 FY26, a substantial turnaround from a loss in the prior year. For the full year FY26, net profit stood at ₹111.08 lakh, also a significant improvement. The company confirmed an unmodified audit opinion.
Read the summary - Low impact
Vineet Labs Q1FY27 Monitoring Report: Rs 2,996.81 Lakhs Rights Issue Funds Utilized
Vineet Laboratories Limited's Monitoring Agency Report for Q1FY27 details the utilization of ₹2,996.81 lakhs from its Rights Issue. As of June 30, 2026, ₹1,352.24 lakhs were utilized. Significant amounts remain unutilized for plant expansion and effluent treatment. Delays in implementation are noted, with revised plans approved.
Read the summary - Low impact
Vineet Labs Exempt from Corporate Governance Compliance for Q1 FY27
Vineet Laboratories Limited is exempt from Corporate Governance compliance for Q1 FY27 due to its paid-up equity capital of ₹9.22 Crore and net worth of ₹3.30 Crore as of March 31, 2025, which are below SEBI's prescribed limits.
Read the summary - Low impact
Vineet Laboratories Files SEBI Compliance Certificate for Q1 FY27
Vineet Laboratories Limited submitted a certificate for Q1 FY27 compliance with SEBI (Depositories and Participants) Regulations, 2018. No securities were processed for dematerialization or rematerialization during the quarter ended June 30, 2026.
Read the summary - Medium impact
Vineet Laboratories MD Gaddam Venkata Ramana Ceases Office on July 21, 2026
Mr. Gaddam Venkata Ramana has ceased to be the Managing Director of Vineet Laboratories Limited, effective July 21, 2026. He will continue to serve as a Director. Mr. Ramana is part of the Promoter and Promoter Group and holds 4,71,000 equity shares.
Read the summary - Low impact
Vineet Laboratories Appoints Rajesh Kumar Kathulla as Additional Director
Vineet Laboratories Limited appointed Mr. Rajesh Kumar Kathulla as an Additional Director (Executive Category) on June 11, 2026. His appointment is subject to shareholder approval. Mr. Kathulla brings over a decade of entrepreneurial experience across diverse sectors.
Read the summary - Low impact
Vineet Laboratories defers Board Meeting scheduled for July 15, 2026.
Vineet Laboratories Limited has deferred its Board Meeting, initially set for July 15, 2026, which was to approve audited financial results for FY26. A new date will be announced soon due to unforeseen circumstances.
Read the summary - Medium impact
Vineet Laboratories Board Meeting on July 15, 2026, to approve Q4 & FY26 Audited Standalone Financial Results
Vineet Laboratories Limited will hold a Board Meeting on July 15, 2026. The meeting will approve the Audited Standalone Financial Results for Q4 and FY ended March 31, 2026. The trading window remains closed until 48 hours post-results declaration.
Read the summary - Medium impact
Vineet Labs Defers Audited Standalone Financial Results; Company Secretary Resigns
Vineet Laboratories Limited deferred its Board Meeting scheduled for May 30, 2026, to approve audited standalone financial results for the quarter and year ended March 31, 2026. The Audit Committee had not recommended the results. The Company Secretary has also resigned. A new date will be announced.
Read the summary - Low impact
Vineet Laboratories: Company Secretary & Compliance Officer Resigns
Mr. Ramesh Kumar Bandari has resigned from his roles as Company Secretary and Compliance Officer of Vineet Laboratories Limited. His resignation is effective May 29, 2026, citing personal reasons. He will also cease to be Key Managerial Personnel.
Read the summary - Low impact
Vineet Labs: Monitoring Agency Report for Q4 FY26 Highlights Fund Utilization
Vineet Laboratories Limited's Monitoring Agency Report for Q4 FY26 shows utilization of Rights Issue proceeds. Gross proceeds were ₹2,996.81 lakhs. As of March 31, 2026, ₹1,352.24 lakhs were utilized, with ₹1,643.94 lakhs remaining. Funds were used for loan repayment, effluent plant, business expansion, and general corporate purposes. Delays in project implementation are noted, with plans for future utilization.
Read the summary - Low impact
Vineet Labs Exempt from Corporate Governance Filing for Q4FY26 Due to Capital Thresholds
Vineet Laboratories Limited is exempt from filing its Q4FY26 Corporate Governance report. The company's paid-up equity capital (₹9.22 crore) and net worth (₹3.30 crore) as of March 31, 2025, are below the regulatory thresholds of ₹10 crore and ₹25 crore, respectively.
Read the summary - Low impact
Vineet Laboratories Files Q4 Compliance Certificate for Structural Digital Database
Vineet Laboratories Limited submitted its Q4 compliance certificate for the Structural Digital Database, ending March 31, 2026. The company confirmed a functional SDD with controlled access and comprehensive UPSI capture, maintained for eight years as per SEBI (PIT) Regulations, 2015.
Read the summary - Low impact
Vineet Laboratories Files SEBI Compliance Certificate for Q4 FY26
Vineet Laboratories Limited submitted a compliance certificate for Q4 FY26 and the full financial year ended March 31, 2026. The certificate from Venture Capital and Corporate Investments Private Limited confirms no securities were dematerialized or rematerialized during the quarter.
Read the summary - Low impact
Vineet Laboratories: Trading Window Closed April 1 to Post-Q4 Results Announcement
Vineet Laboratories Limited will close its trading window from April 1, 2026, until 48 hours after the announcement of Q4 and FY26 financial results. This is in line with SEBI regulations. The company will also freeze the PAN of designated persons during this period.
Read the summary - Low impact
Vineet Laboratories Publishes Q3 & Nine Months FY26 Unaudited Standalone Financial Results
Vineet Laboratories Limited published its unaudited standalone financial results for Q3 and the nine months ended December 31, 2025. The results were published on February 16, 2026, and are available on the company's website and stock exchange portals.
Read the summary - Low impact
Vineet Laboratories Q3 FY26 Unaudited Standalone Results Approved; Vendor Payments Ratified
Vineet Laboratories Limited's Board approved unaudited standalone financial results for Q3 FY26 ended December 31, 2025. The company also ratified vendor payments for equipment for its new production facility, as mentioned in the December 17, 2025 Rights Issue Letter of Offer.
Read the summary - Low impact
Vineet Labs Q3 FY26 Unaudited Standalone Results Approved; Payments for Quality Control Equipment Ratified
Vineet Laboratories Limited's Board approved unaudited standalone financial results for Q3 FY26 ended December 31, 2025. Payments for Quality Control and RO Water equipment were also approved and ratified, intended for the new production facility mentioned in the December 17, 2025 Rights Issue Letter of Offer. The Board meeting concluded on February 14, 2026.
Read the summary - Medium impact
Vineet Laboratories Limited Concludes EGM: Appoints Ms. Jasmin Kunal Tailor as Independent Director
Vineet Laboratories Limited held an EGM on February 07, 2026, to appoint Ms. Jasmin Kunal Tailor as an Independent Director. The special resolution passed with 1,219,216 votes in favor out of 1,219,294 votes polled. The Scrutinizer's report confirms the outcome.
Read the summary - Low impact
Vineet Laboratories Limited Holds EGM on Feb 7, 2026, Appoints Jasmin Kunal Tailor as Independent Director
Vineet Laboratories Limited held an EGM on February 07, 2026, to appoint Ms. Jasmin Kunal Tailor as an Independent Director. The meeting was conducted via video conferencing and concluded with the transaction of this key resolution. Voting results will be submitted to stock exchanges.
Read the summary - Medium impact
Vineet Laboratories Limited: Trading Approval Received for Rights Issue Shares from BSE & NSE
Vineet Laboratories Limited received trading approval from BSE and NSE for its rights issue shares. 99,87,258 equity shares are listed and admitted to dealings from February 05, 2026. The shares were issued at a premium of Rs. 20/-.
Read the summary - Medium impact
Vineet Labs Completes Rights Issue Allotment, Trading to Commence Soon
Vineet Laboratories Limited has completed its Rights Issue, allotting 99,87,258 equity shares. The issue was oversubscribed at 103.25%. Trading of the rights equity shares is expected to commence on or about February 03, 2026. Advertisements regarding the allotment were published on February 04, 2026.
Read the summary - Medium impact
Vineet Laboratories Allots 99.87 Lakh Equity Shares via Rights Issue at ₹30
Vineet Laboratories Limited allotted 99,87,258 equity shares via a rights issue at ₹30 per share on February 02, 2026. This increases the company's paid-up capital to ₹19,20,62,660.
Read the summary - Low impact
Vineet Laboratories Extends Rights Issue Closing Date to January 30
Vineet Laboratories Limited has extended its Rights Issue closing date to January 30, 2026. This decision was made by the Rights Issue Committee on January 13, 2026, to allow more time for shareholders to participate. The company has published notices in Financial Express, Jansatta, and Nava Telangana regarding the extension.
Read the summary - Low impact
Vineet Laboratories Limited Announces Extra-Ordinary General Meeting
Vineet Laboratories Limited has announced an Extra-Ordinary General Meeting (EGM) with e-voting information. The notice was published in newspapers on January 13, 2026, and is available on the company's website.
Read the summary - Low impact
Vineet Labs Extends Rights Issue Closing Date to Jan 30, 2026
Vineet Laboratories Limited has extended its Rights Issue. The last date for on-market renunciation is now January 27, 2026, and the issue closing date is January 30, 2026. Allotment and listing of shares are scheduled for February 2-3, 2026.
Read the summary - Low impact
Vineet Labs submits SEBI compliance certificate for Q3 FY26
Vineet Laboratories Limited submitted a SEBI compliance certificate for the quarter ended December 31, 2025. The certificate, issued by Venture Capital and Corporate Investments Private Limited, confirms no securities were dematerialized or rematerialized during the period.
Read the summary - Medium impact
Vineet Laboratories Appoints Jasmin Tailor as Independent Director, Sets EGM Dates
Vineet Laboratories' Board approved appointing Ms. Jasmin Kunal Tailor as Independent Director. An EGM is scheduled for shareholder approval. Cut-off dates for notice and voting eligibility are Jan 9 and Jan 30, 2026, respectively. Remote e-voting will be open from Feb 4 to Feb 6, 2026.
Read the summary - Low impact
Vineet Laboratories Announces Newspaper Publication for Rights Issue
Vineet Laboratories Limited has published newspaper advertisements for its Rights Issue. The issue offers up to 99,87,258 equity shares at ₹30 each, aggregating up to ₹29.96 crore. The record date was December 23, 2025, and the issue closes on January 21, 2026. Dispatch of offer documents was completed on December 24, 2025.
Read the summary - Low impact
Vineet Laboratories Limited Closes Trading Window for Q3 FY26 Results
Vineet Laboratories Limited will close its trading window from January 1, 2026, until 48 hours after the announcement of its Q3 FY26 financial results. The company has ensured PAN freezing for designated persons during this period. The board meeting date for results declaration will be intimated later.
Read the summary - Medium impact
Vineet Labs Rights Issue: Letter of Offer Approved, Filing with SEBI
Vineet Laboratories Limited is undertaking a Rights Issue of 99,87,258 equity shares at ₹30 each, aiming to raise ₹29.97 Crores. The record date is December 23, 2025. The issue opens on January 01, 2026, and closes on January 21, 2026. The Letter of Offer has been submitted to SEBI.
Read the summary - Low impact
Vineet Laboratories: ISIN for Rights Entitlements Announced
Vineet Laboratories Limited has announced the ISIN INE505Y20010 for its Rights Entitlements. These entitlements will be credited to eligible shareholders' demat accounts before the rights issue opens, following SEBI guidelines.
Read the summary - Medium impact
Vineet Laboratories Announces Rights Issue of ₹29.96 Crore at ₹30 Per Share
Vineet Laboratories is launching a rights issue of ₹29.96 crore, offering 99,87,258 equity shares at ₹30 each. The record date is December 23, 2025. The issue opens on January 1, 2026, and closes on January 21, 2026. Shareholders will receive 13 rights shares for every 12 held.
Read the summary - Medium impact
Vineet Labs Approves Rights Issue of 99.87 Lakh Shares Worth ₹29.96 Crore
Vineet Laboratories Limited's Rights Issue Committee approved a Rights Issue of 99,87,258 equity shares at ₹30 each, aggregating ₹29.96 crore. The issue opens on January 1, 2026, and closes on January 21, 2026. The record date is December 23, 2025.
Read the summary - Medium impact
Vineet Laboratories Receives In-Principle Approval for Rights Issue from BSE and NSE
Vineet Laboratories Limited received in-principle approval from NSE on December 02, 2025, and BSE on December 16, 2025, for a Rights Issue. The Board will meet on December 17, 2025, to approve issue price, ratio, and dates for the up to ₹30 Crore rights issue.
Read the summary - Medium impact
Vineet Laboratories Adjourns Rights Issue Committee Meeting to Dec 17
Vineet Laboratories Limited's Rights Issue Committee meeting scheduled for December 16, 2025, has been adjourned to December 17, 2025. The committee will decide on issue price, entitlement ratio, record date, and opening/closing dates, pending BSE's in-principle approval.
Read the summary - Medium impact
Vineet Laboratories Rights Issue Committee Meeting Adjourned to Dec 16
Vineet Laboratories Limited's Rights Issue Committee meeting, scheduled for December 15, 2025, has been adjourned to December 16, 2025. The committee will discuss issue price, entitlement ratio, record date, and opening/closing dates, pending BSE approval.
Read the summary - Low impact
Vineet Labs Rights Issue Committee Meeting Adjourned to Dec 15
Vineet Laboratories Limited adjourned its Rights Issue Committee meeting to December 15, 2025. The committee will decide on issue price, entitlement ratio, record date, and opening/closing dates for the proposed Rights Issue, pending BSE approval.
Read the summary - Medium impact
Vineet Laboratories Rights Issue Committee Meeting Adjourned to Dec 12
Vineet Laboratories' Rights Issue Committee meeting adjourned to December 12, 2025. The committee will decide on Issue Price, Entitlement Ratio, Record Date, and opening/closing dates, pending BSE approval.
Read the summary - Low impact
Rights Issue Committee Meeting Adjourned to December 11, 2025
Vineet Laboratories Limited's Rights Issue Committee meeting on December 9, 2025, adjourned to December 11, 2025, to finalize issue details pending BSE approval.
Read the summary - Low impact
Rights Issue Committee Meeting Adjourned to December 9, 2025
Vineet Laboratories Limited's Rights Issue Committee meeting on December 6, 2025, has been adjourned to December 9, 2025, pending BSE approval and further deliberation on issue details.
Read the summary - Low impact
Rights Issue Committee Meeting Adjourned to December 6, 2025
Vineet Laboratories' Rights Issue Committee meeting on Dec 3, 2025, adjourned to Dec 6, 2025, to finalize issue details pending BSE approval.
Read the summary - Medium impact
Vineet Laboratories to consider Rights Issue details on Dec 3, 2025
Vineet Laboratories to consider Rights Issue details on Dec 3, 2025
Read the summary - Medium impact
Submission of Draft Letter of Offer for Rights Issue
Vineet Laboratories Limited submitted the Draft Letter of Offer for the proposed Rights Issue to BSE and NSE on November 27, 2025. The document is available on the company website.
Read the summary - Medium impact
Vineet Laboratories Board approves rights issue up to ₹3,000 Lakhs
Vineet Laboratories board approves raising funds via rights issue of equity shares of face value ₹10 each for an aggregate amount not exceeding ₹3,000 Lakhs. Record date will be notified later.
Read the summary - Medium impact
Vineet Laboratories Board Approves Rights Issue Up to ₹30 Crore
Vineet Laboratories' board approved raising up to ₹30 crore through a rights issue of equity shares. A committee has been formed to manage the process, subject to regulatory approvals.
Read the summary
Model portfolios
Filings are the raw material. These are what SEBI-registered experts build from them.
- Stocks
Udaan
Fast-growing, less-covered companies still early in their runway.
Aggressive29 holdings5+ yearsView portfolio - Stocks
Bharat Rising
Built around India's own shifts: capex, household savings, energy and consumption.
Moderate-Aggressive25 holdings3+ yearsView portfolio - Stocks
All-Terrain
One equity portfolio instead of three: large, mid and small cap in a single book.
Moderate-Aggressive34 holdings3+ yearsView portfolio - Stocks
Core Compounders
Companies that have already been through a downturn and came out still growing.
Moderate20 holdings3+ yearsView portfolio